P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
Status:
Active, not recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate whether genomic based risk-stratification
can be used in deciding whether to de-intensify in patients with Human Papillomavirus
(HPV)-associated Oropharyngeal Squamous Cell Carcinoma (OPSCC) with > 10 pack years smoking
history. Hypothesis: Patients with HPV-associated OPSCC, > 10 pack years smoking history, and
non-mutated p53 will have similar 2 year progression-free survival (PFS) as patients with <
10 pack years smoking history.